Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 380

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

Open access
Mehnert, Janice M., Panda, Anshuman, Zhong, Hua, Hirshfield, Kim, Damare, Sherri, Lane, Katherine, Sokol, Levi, Stein, Mark N., Rodriguez-Rodriquez, Lorna, Kaufman, Howard L., Ali, Siraj, Ross, Jeffrey S., Pavlick, Dean C., Bhanot, Gyan, White, Eileen P., DiPaola, Robert S., Lovell, Ann, Cheng, Jonathan, Ganesan, Shridar·2016·Journal of Clinical Investigation

Abstract

Results and DiscussionA 53-year-old woman presenting with irregular vaginal bleeding was treated with hysterectomy and diagnosed with a pT1b pN0, stage IB, FIGO grade III endometrial adenocarcinoma, high-grade endometrioid type, with extensive necrosis, lymphovascular invasion, and myometrial invasion.A peritumoral lym-Antibodies that target the immune checkpoint receptor programmed cell death protein 1 (PD-1) have resulted in prolonged and beneficial responses toward a variety of human cancers.However, anti-PD-1 therapy in some patients provides no benefit and/or results in adverse side effects.The factors that determine whether patients will be drug sensitive or resistant are not fully understood; therefore, genomic assessment of exceptional responders can provide important insight into patient response.Here, we identified a patient with endometrial cancer who had an exceptional response to the anti-PD-1 antibody pembrolizumab.Clinical grade targeted genomic profiling of a pretreatment tumor sample from this individual identified a mutation in DNA polymerase epsilon (POLE) that associated with an ultramutator phenotype.Analysis of The Cancer Genome Atlas (TCGA) revealed that the presence of POLE mutation associates with high mutational burden and elevated expression of several immune checkpoint genes.Together, these data suggest that cancers harboring POLE mutations are good candidates for immune checkpoint inhibitor therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci84940

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 380

Metadata

Authors
Mehnert, J. M., Panda, A., Zhong, H., Hirshfield, K., Damare, S., Lane, K., Sokol, L., Stein, M. N., Rodriguez-Rodriquez, L., Kaufman, H. L., Ali, S., Ross, J. S., Pavlick, D. C., Bhanot, G., White, E. P., DiPaola, R. S., Lovell, A., Cheng, J., & Ganesan, S.
Venue
Journal of Clinical Investigation
Published
2016-05-09
Volume
126
Issue
6
Pages
2334-2340
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2383119765
Cited by
380
References
8
FWCI
21.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. https://app.cochat.ai/papers/10.1172/jci84940
The paper
Mehnert, J. M., Panda, A., Zhong, H., Hirshfield, K., Damare, S., Lane, K., Sokol, L., Stein, M. N., Rodriguez-Rodriquez, L., Kaufman, H. L., Ali, S., Ross, J. S., Pavlick, D. C., Bhanot, G., White, E. P., DiPaola, R. S., Lovell, A., Cheng, J., & Ganesan, S. (2016). Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci84940

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.